Note 13 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule Of Loss Before Provision For Income Taxes

The components of loss before provision for income taxes were as follows:

	Years Ended December 31,
	2022		2021
Domestic	$	(225,127)	$	(159,632)
Foreign	(19,256)		(22,177)
Loss before provision for income taxes	$	(244,383)	$	(181,809)

Schedule of Components of Income Tax (Benefit) Expense

The components of the (benefit) expense for income taxes were as follows:

	Years Ended December 31,
	2022		2021
Current expense provision:
U.S. Federal and state	$	2,430	$	2,179
Foreign	292		233
Total current expense provision	2,722		2,412
Deferred expense (benefit) provision:
U.S. Federal and state	11		(159)
Total expense provision	$	2,733	$	2,253

Summary Of The Differences Between The Company's Effective Tax Rate And Statutory Tax Rate

The differences between the Company’s effective tax rate and the statutory tax rate in 2022, 2021, and 2020, are as follows:

	2022		2021		2020
Income tax benefit at federal statutory rate (21% for 2022, 2021 and 2020)	$	(51,321)	$	(38,175)	$	(38,391)
State and local income taxes net of federal tax benefit	(1,816)		(2,288)		(2,544)
Permanent items	(1,608)		(1,343)		774
Rate change	—		—		(82)
Expiration of attribute carryforwards	—		(1,057)		3,774
Research and development tax credits	(9,793)		(5,994)		(4,080)
Foreign rate differential	1,862		1,940		542
Other	(5,485)		1,216		1,456
Change in valuation allowance	70,894		47,954		38,551
Income tax expense	$	2,733	$	2,253	$	—

Schedule Of Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	2022		2021
Balance at January 1,	$	9,729	$	8,230
Additions to current period tax positions	4,115		1,499
Balance at December 31,	$	13,844	$	9,729

Schedule Of Deferred Tax Assets And Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows:

	2022		2021
Deferred tax assets:
Net federal and state operating losses	$	101,600	$	113,649
Research and development credits	86,321		71,197
Royalty income	115,554		106,007
Stock-based compensation	19,374		14,512
Capitalized R&D	62,794		8,997
Leasing obligations	1,842		1,836
Other	4,354		4,809
Total deferred tax assets	391,839		321,007
Deferred tax liabilities:
Fixed assets	(717)		(607)
Right of use asset	(1,525)		(1,527)
Total deferred tax liabilities	(2,242)		(2,134)
Valuation allowance	(389,608)		(318,714)
Net deferred tax assets (liabilities)	$	(11)	$	159